Applications of Z-Asp(OMe)-OH in Industrial Manufacturing

Z-Asp(OMe)-OH, known scientifically as N-α-Carbobenzyloxy-L-Aspartic Acid β-Methyl Ester, is a specialized amino acid derivative. As a direct manufacturer, we supply this material to multiple sectors that require high purity and consistency for downstream synthetic processes. Our production supports strict compliance and traceability, meeting industrial demand for reliable sourcing in advanced chemical synthesis.

1. Peptide Therapeutics Synthesis

This compound serves as a protected aspartic acid building block in solid-phase peptide synthesis (SPPS) and solution-phase routes for commercial APIs. Pharmaceutical manufacturers depend on its orthogonal protection and methyl ester group for selective chain extension and deprotection schemes. Its use enhances chain integrity and reduces racemization, crucial in GMP environments for scale-up to injectable and oral polypeptide drugs.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice Guidelines
• US Pharmacopeia (USP) monographs for peptide APIs
• European Pharmacopoeia (Ph. Eur.) Chapter 5.10
• FDA 21 CFR Part 210/211 Pharmaceutical GMP

Typical usage ratio

• 15–28 mol% of protected amino acid mixture during chain assembly, depending on peptide sequence
• Adjusted to maintain equimolar ratio with coupling reagents and resin load

Downstream process integration

• Loaded onto resin during initial peptide elongation in automated SPPS reactors
• Retained through HBTU/HATU-mediated coupling, with subsequent selective Z-deprotection prior to final cleavage

Final product types

• GLP-1 peptide APIs
• Cosmetic peptides for anti-aging products
• Custom research peptides
• Pharmaceutical-grade oligopeptides

2. Enzyme Substrate Analogue Manufacturing

Enzyme and diagnostic kit makers utilize this compound as a key intermediate for substrate analogue synthesis. The ester and Z-protection prevent premature hydrolysis, allowing sequential modification to the side chain for substrate design in research and high-throughput screening tools. The purity and configuration integrity of Z-Asp(OMe)-OH ensure analytical reproducibility.

Industry compliance standards

• ISO 13485:2016 for IVD reagent components
• Quality control protocols under CLSI guidelines
• Analytical-grade purity requirements per ACS standards

Typical usage ratio

• 10–22 mol% in substrate preparation batches, varying by assay scale
• Adjusted based on desired substrate concentration and enzyme kinetic studies

Downstream process integration

• Introduced during active group derivatization, commonly before side-chain modifications
• Subjected to selective deprotection and further linkage to chromogenic or fluorogenic probes

Final product types

• Enzyme assay calibrator substrates
• Inhibitor screening kits
• Diagnostic test kits for synthetic substrate detection
• Research use only (RUO) substrate standards

3. Specialty Polymer Synthesis for Bioengineering

Manufacturers of biomedical hydrogels and tissue engineering matrices incorporate this material as a protected aspartic acid monomer for copolymerization. Its Z- and methyl ester functions enable selective modification for grafting onto biodegradable polymer backbones. Reliable lot-to-lot purity supports reproducible polymer performance and controlled release characteristics required for medical device applications.

Industry compliance standards

• ISO 10993-1 Biological Evaluation of Medical Devices
• USP Class VI Plastic Biocompatibility
• ISO 13485:2016 Medical Device QMS

Typical usage ratio

• 2–8 wt% of total monomer blend per batch
• Ratio fine-tuned according to desired cross-link density and degradation profile

Downstream process integration

• Added as comonomer in in-situ radical or condensation polymerization under inert conditions
• Unmasked and further functionalized before or after backbone integration, depending on end-use

Final product types

• Injectable hydrogels for wound healing
• Biodegradable matrices for drug delivery systems
• 3D-printable scaffolds for regenerative medicine
• Functionalized polymers for cell culture supports

4. Chiral Intermediate for Agrochemical Synthesis

Agrochemical manufacturers use this compound as a chiral synthon for synthesizing selective herbicide and fungicide active ingredients. The protected functionality helps to build enantiomerically pure intermediates, which are necessary for high-activity, target-specific crop protection agents with improved environmental profiles. Integration in stepwise synthesis maximizes yield and chemical selectivity.

Industry compliance standards

• FAO specifications for pesticide active substances
• EU Regulation (EC) No 1107/2009 (plant protection product approval)
• REACH chemical registration for intermediates

Typical usage ratio

• 4–12 mol% in multi-step synthesis, tailored for product-specific reaction pathway
• Ratio adjusted according to target intermediate yield and purity requirements

Downstream process integration

• Fed into early-stage chiral center construction during batch or continuous synthesis
• Undergoes selective deprotection and functional group conversion to match target compound architecture

Final product types

• Chiral herbicide active pharmaceutical ingredients
• Selective fungicide intermediates
• Crop-specific agrochemical end-products
• Stereochemically pure plant growth regulators

5. Custom Amino Acid Derivative Manufacturing for Research Reagents

Producers of complex chemical synthesis reagents employ Z-Asp(OMe)-OH as a raw material for tailoring novel derivatives demanded by academic and industrial R&D laboratories. Its dual protection profile is valuable for sequential and orthogonal deprotection strategies, which enable structural diversification during small molecule, labeling, or cross-linking agent development.

Industry compliance standards

• ISO 9001:2015 Quality Management System
• Analytical characterization in line with ACS reagent grades
• Documentation and traceability per GLP (Good Laboratory Practice) where applicable

Typical usage ratio

• 5–18 mol% in advanced synthetic transformations
• Variation depends on the complexity and protective group strategy in R&D formulations

Downstream process integration

• Combined with activating agents for subsequent derivatization, linker attachment, or labeling steps
• Deprotection sequence manipulated based on researcher-specific synthetic routes

Final product types

• Activated amino acid derivatives
• Site-specific protein labeling agents for bioconjugation
• Chemical cross-linkers for protein and surface analysis
• Reactive building blocks for combinatorial chemistry kits